Cellzome awarded UK’s Technology Strategy Board grant as part of the Regenerative Medicine Programme
Three grants have been awarded this year which demonstrate the broad utility of Cellzome’s unique chemoproteomics platform
Advertisement
Cellzome announced the award of a grant by the UK government-backed Technology Strategy Board under its regenerative medicine Programme: “Tools and Technologies” for a project which will address the need for better characterisation of human stem cells. Cellzome will use its EpisphereTM technology in collaboration with Pfizer Ltd (Neusentis), the University of Sheffield and Plasticell Limited to identify protein fingerprints which are predictive of potentially deleterious changes in the stem cells. The project will be led by Cellzome and the funding will amount to €1.1M (GBP 0.9M) over a period of two years.
This is the third grant awarded this year that leverages Cellzome’s unique position in chemoproteomics and supports the company’s innovative approaches to drug discovery.
Other news from the department business & finance
